Steven Breazzano
ABOUT
Steven currently focuses his analyses primarily on the valuation of smaller biotechs (100MM to 1 BB market cap) and utilizes all sources of information, including conversations with management, peer-reviewed publications, and SEC filings.
Steven has done extensive work in the field of synthesis of biologically relevant compounds and new organic reaction development – publishing several papers in prestigious peer-reviewed journals including Angewandte Chemie and the Journal of the American Chemical Society. He is currently pursuing the Chartered Financial Analyst (CFA) designation (completed exam level 2, June 2012) as well as a PhD. as an NSF predoctoral fellow in synthetic and biological chemistry at the ...More
Steven has done extensive work in the field of synthesis of biologically relevant compounds and new organic reaction development – publishing several papers in prestigious peer-reviewed journals including Angewandte Chemie and the Journal of the American Chemical Society. He is currently pursuing the Chartered Financial Analyst (CFA) designation (completed exam level 2, June 2012) as well as a PhD. as an NSF predoctoral fellow in synthetic and biological chemistry at the ...More
SNAPSHOT
- Description: Doctoral student. Trading frequency: Monthly
- Interests: Options, Stocks - long, Stocks - short
COMPANY
Currently, there is no company profile for Steven Breazzano.
BLOG
The Biotech Investment Paradigm
The Biotech Investment Paradigm covers biopharmaceutical companies with market caps from approximately $50 million to $1 billion. We believe this niche offers tremendously high return and – when handled properly - acceptable risk. It is our goal to assist investors with a portion of the due diligence ...More
Book
Currently, there are no book details for Steven Breazzano.
Latest Comments
more »
Latest comments on Steven's Articles
LATEST ARTICLES & INSTAPOSTS
more »